Private insurers decline to cover Biogen's new Alzheimer's drug in escalating standoff — report
As the fallout continues from the FDA’s controversial approval of Biogen’s new Alzheimer’s drug Aduhelm, some insurers are reportedly unwilling to cover the high costs associated with the drug.
At least six affiliates of Blue Cross Blue Shield across the country have adopted new policies describing Aduhelm as either “experimental” or “investigational,” the Boston Globe reported Tuesday evening, saying the drug falls outside covered medicines because it remains under clinical review. The report came a day after the Centers for Medicare & Medicaid Services opened a nine-month review process over limiting coverage of Aduhelm, which is priced at $56,000 per year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
